Vicarious Surgical Inc [RBOT] stock prices are up 57.11% to $0.54 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RBOT shares have gain 54.29% over the last week, with a monthly amount glided 31.77%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 20, February 2024, Vicarious Surgical to Participate in TD Cowen’s 44th Annual Healthcare Conference. In a post published today on Yahoo Finance, Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the Company will participate in the TD Cowen 44th Annual Healthcare Conference.
From an analyst’s perspective:
Vicarious Surgical Inc [NYSE: RBOT] stock has seen the most recent analyst activity on March 04, 2022, when Piper Sandler downgraded its rating to a Neutral and also revised its price target to $7 from $16. Previously, Credit Suisse started tracking the stock with Outperform rating on January 07, 2022, and set its price target to $16. On December 07, 2021, Cowen initiated with a Outperform rating and assigned a price target of $15 on the stock. Canaccord Genuity started tracking the stock assigning a Buy rating and suggested a price target of $15 on November 05, 2021. BTIG Research initiated its recommendation with a Buy and recommended $15 as its price target on October 18, 2021. Piper Sandler started tracking with a Overweight rating for this stock on October 07, 2021, and assigned it a price target of $16.
The stock price of Vicarious Surgical Inc [RBOT] has been fluctuating between $0.20 and $2.92 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Vicarious Surgical Inc [NYSE: RBOT] shares were valued at $0.54 at the most recent close of the market. An investor can expect a potential return of 1011.11% based on the average RBOT price forecast.
Analyzing the RBOT fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3891 points at the first support level, and at 0.2383 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6454, and for the 2nd resistance point, it is at 0.7509.
Vicarious Surgical Inc [RBOT] reported earnings per share of -$0.1 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.14/share, meaning a difference of $0.04 and a surprise factor of 28.60%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.12 per share as compared to estimates of -$0.14 per share, a difference of $0.02 representing a surprise of 14.30%.
Ratios To Look Out For
It’s worth pointing out that Vicarious Surgical Inc [NYSE:RBOT]’s Current Ratio is 14.53. In addition, the Quick Ratio stands at 14.53 and the Cash Ratio stands at 0.05.
Transactions by insiders
Recent insider trading involved Sachs Adam David, CEO, that happened on Feb 20 when 28282.0 shares were sold. Chief Technology Officer, Khalifa Sammy completed a deal on Feb 20 to sell 22625.0 shares. Meanwhile, CFO and Treasurer Kelly William John sold 7555.0 shares on Feb 20.
